This program is based on an inhibitor of TAK1, which is a central mediator, or a kind of switch, for various inflammatory signals and for activation of several inflammatory mediators (cytokines).

The program (Alnitak) began in the fall of 2019 and on February 15, 2023, Aqilion signed an exclusive license agreement and strategic research collaboration with Merck to discover, develop and commercialize small-molecule inhibitors of TAK1. June 20, 2024 Aqilion announced that Aqilion and Merck have decided to terminate the joint development of the TAK1 program. Data generated in the course of the collaboration have altered the risk-benefit profile within the intended indications. Merck will return all rights according to the licensing and collaboration agreement.